Valion Bio, Inc. current report, 15 August 2022

完整文档

Filing Summary

Registrant: Tivic Health Systems, Inc. The request metadata identifies Valion Bio, Inc., but the supplied filing names Tivic Health Systems, Inc. as the registrant.

Form and date: Form 8-K filed August 15, 2022, reporting on the company’s second fiscal quarter ended June 30, 2022.

Business Context and Reporting Period

The filing reports that Tivic issued a press release concerning its second-quarter 2022 financial results and introduced a new corporate presentation. The filing identifies the company’s common stock as trading under the symbol TIVC on Nasdaq.

Financial Metrics

  • Revenue, net income or loss, cash flow, margins, debt, liquidity, and other financial metrics are not included in the supplied filing text.
  • The referenced financial results press release is furnished as Exhibit 99.1, but its contents were not provided.

Material Changes Versus Prior Period

The filing text does not provide a clear comparison with the prior comparable period. Any changes in operating or financial performance would need to be verified in Exhibit 99.1.

Guidance, Outlook, Risks, and Unusual Items

  • A new corporate presentation dated August 2022 was furnished as Exhibit 99.2; its contents were not provided.
  • The filing contains customary forward-looking statement language and warns that actual results may differ materially because of known and unknown risks and uncertainties.
  • No specific guidance, contingency, financing, debt action, or unusual accounting item is disclosed in the supplied text.
  • Items 2.02 and 7.01 information, including the exhibits, was furnished rather than filed for purposes of Section 18 of the Exchange Act.

Investor Verification Items

  1. Confirm the correct issuer, since the metadata names Valion Bio, Inc. while the filing names Tivic Health Systems, Inc.
  2. Review Exhibit 99.1 for second-quarter revenue, profitability, cash position, cash usage, margins, and year-over-year comparisons.
  3. Review Exhibit 99.2 for management’s business update, strategy, milestones, and any outlook or guidance.
  4. Assess the forward-looking statements against the risk factors and subsequent liquidity or financing disclosures.